RT Journal Article
SR Electronic
T1 Dramatic drop of new SARS-CoV-2 infections among health care workers after the first dose of the BNT162b2 mRNA Covid-19 Vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.24.21254238
DO 10.1101/2021.03.24.21254238
A1 Guijarro, Carlos
A1 Galán, Isabel
A1 Martínez-Ponce, Diana
A1 Pérez-Fernández, Elia
A1 José Goyanes, Maria
A1 Castilla, Virgilio
A1 Velasco, María
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2021.03.24.21254238.abstract
AB Objectives To evaluate the effect of mRNA SARS-Cov-2 vaccination on the incidence of new SARS-CoV-2 infections in health care workers (HCW).Methods The evolution of the incident rate of SARS-CoV-2 infection in a cohort of 2590 HCW after a mRNA SARS-CoV-2 vaccination was assessed, as compared to the rate in the community (n=170513). SARS-CoV-2 infections were microbiologically confirmed by an antigen, a CRP positive test, or both.Results A total of 1820 HCW (70,3% of total) received the first dose of the vaccine between January 10-16, 2021), and 296 (11,4%) the following week. All of them completed vaccination 3 weeks later. New SARS-COV-2 infections in HCW declined by 62% at 2-4 weeks after the first dose of mRNA SARS-CoV-2 vaccination and virtually disappeared after the second dose of the vaccine. Vaccination rate was negligible for this time period in the community (<5%). The decline in the incident rate of SARS-COoV-2 new infection in HCW shortly after the administration of the first dose of the vaccine was strikingly higher than the reduction observed in the general population (p<0.001and became even more pronounced after the second dose of the vaccine (p<0.001).Conclusions mRNA SARS-CoV-2 vaccination is associated with a dramatic decline in new SARS-CoV-2 infection among HCW, even before the administration of the second dose of the vaccine.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo fundingsAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The estudy was apprroved by the Independent Review Board - Ethics Committee for Drug Research of Hospital Universitario Fundacion AlcorconAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData may be available upon request